drugset
drugset / Trial / NCT05005975

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05005975 ↗

Phase 3 Recruiting 301 enrolled Tanabe Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the long-term safety and tolerability of oral dersimelagon.

Timeline

Start
2021-08-10
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dersimelagon Small molecule 200 mg Oral

Indications

X-linked erythropoietic protoporphyria